Welcome to our dedicated page for Alamar Biosciences SEC filings (Ticker: ALMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Alamar Biosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Alamar Biosciences's regulatory disclosures and financial reporting.
Alamar Biosciences Chief Financial Officer Justin J. McAnear reported new equity awards and an option restructuring. He received 37,220 shares of Common Stock as restricted stock units that vest monthly from the grant date, conditioned on his continued service.
He was also granted stock options for 163,358 shares of Common Stock at an exercise price of $17.00 per share, with 25% vesting on April 16, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continued service. In addition, 570,719 stock options with a $4.62 exercise price were reclassified so the underlying security changed from Class B Common Stock to Common Stock in connection with the company’s initial public offering, with no open-market buying or selling reported.
Alamar Biosciences director Nicholas Naclerio reported multiple equity-related transactions. An entity associated with him purchased 235,294 shares of Common Stock at $17.00 per share, increasing indirect ownership. He also received 5,686 restricted stock units that vest in three equal installments on April 20, 2027, April 20, 2028 and April 20, 2029, contingent on continued service.
In addition, he was granted a stock option for 25,599 shares at an exercise price of $17.00 per share, vesting from April 16, 2027 through April 16, 2029 and expiring on April 15, 2036. Several series of Preferred Stock and a convertible promissory note held by Illumina Innovation Fund entities automatically converted into Class B Common Stock, which was then reclassified into Common Stock in connection with the company’s IPO, with Naclerio disclaiming beneficial ownership except for his pecuniary interests.
Alamar Biosciences, Inc. completed its initial public offering of common stock on April 20, 2026. The company sold 12,937,500 shares, including 1,687,500 shares from the full exercise of the underwriters’ option, at $17.00 per share, generating approximately $219.9 million in gross proceeds before fees and expenses.
Immediately before the IPO closing, Alamar implemented an amended and restated certificate of incorporation and amended and restated bylaws, previously approved by its board and stockholders, to establish its post‑IPO corporate governance framework.
Alamar Biosciences, Inc. filed a Post-Effective Amendment No. 1 to its Form S-1 (Registration No. 333-294697) to replace Exhibit 5.1. The amendment is limited to Item 16(a) and Exhibit updates and states the registration statement shall become effective upon filing in accordance with Rule 462(d).
Alamar Biosciences, Inc. received an initial Form 3 from several Qiming-affiliated investment vehicles reporting indirect ownership of multiple series of preferred stock. These preferred shares are convertible into Class B Common Stock and will automatically convert into common stock upon the closing of the company’s initial public offering pursuant to their terms.
The filing shows holdings of Series A-3, Series A-4, Series B and Series C Preferred Stock, all with a stated conversion feature and no expiration date. Qiming Corporate GP VI, Ltd., Qiming GP VIII, LLC and Qiming GP VIII-HC, LLC may be deemed to have voting and dispositive power over certain positions but each disclaims beneficial ownership beyond its proportionate pecuniary interest.
Alamar Biosciences director Witney Frank has reported existing stock option holdings for Class B Common Stock. The filing lists three option awards with exercise prices of $0.59, $3.10 and $7.60 per share, covering 49,627, 33,085 and 124,069 underlying shares, expiring between 2031 and 2036.
Footnotes state that one option is fully vested, while others vest in monthly installments over 48 months, with a portion beginning to vest on January 15, 2027 and another measured from January 1, 2025, contingent on continuous service.
Alamar Biosciences, Inc. director Ian W. Ratcliffe filed a Form 3 as an initial statement of his ownership status in company securities. The filing lists him as a director of Alamar Biosciences, Inc. (ticker ALMR) and reports no transactions or derivative positions at this time.
Alamar Biosciences director Rebecca Chambers reported her initial holdings of stock options in the company. The Form 3 shows a stock option covering 140,612 shares of Class B Common Stock with an exercise price of $7.60 per share and an expiration date of January 14, 2036.
According to the filing, 25% of the shares subject to the option vest on January 15, 2027, and the remaining shares vest in equal monthly installments over the following three years, contingent on her continued service with the company. This is a routine disclosure of an equity award rather than a new market transaction.
Alamar Biosciences director Nicholas Naclerio filed an initial Form 3 showing indirect interests in Illumina-affiliated investment funds that hold Alamar securities. The filing lists convertible promissory notes and multiple preferred stock series that are all convertible into Alamar equity.
The Series A-3, Series A-4 and Series C Preferred Stock are each convertible into Class B Common Stock on a 1-for-2.418 basis at the holder’s election and will automatically convert into common stock upon the closing of Alamar’s initial public offering. The Series B Preferred Stock converts into Class B Common Stock on a 1-for-2.271 basis with the same automatic IPO conversion feature.
The filing also describes a convertible note maturing on July 8, 2027, which will automatically convert, together with accrued interest, into common stock at a price equal to 85% of the IPO price. All securities are held by Illumina Innovation Fund II, L.P. and Illumina Innovation Fund III, L.P.; their general partners and Naclerio may be deemed to share voting and investment power but each disclaims beneficial ownership except for any pecuniary interest.
Alamar Biosciences, Inc. Chief Financial Officer Justin J. McAnear reported his initial holdings of a stock option to buy Class B common stock. The option covers 570,719 underlying shares at an exercise price of $4.62 per share and expires on October 14, 2035.
According to the vesting terms, 25% of the shares subject to the option vest on October 13, 2026, and 1/48th of the shares vest monthly thereafter, as long as McAnear continues providing service through each vesting date.